Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241171EnglishN2025January14Healthcare High-Pressure Contrast Injector: Enhancing Patient Safety & Minimizing Adverse Events     English0107Kothwala Dr. Deveshkumar MahendralalEnglish Shaikh AmirhamzahEnglish MahmadiqbalEnglish Khalifa Haroonmohammad RasidmohammadEnglish Bhavsar Girakumari RajubhaiEnglish High Pressure Contrast Injectors are widely used in modern diagnostic imaging, allowing for accurate contrast media delivery to improve visualization in angiography, CT and MRI. They optimize image quality, decreased procedure time, and minimize contrast media dosage, thus fostering patient safety and diagnostic accuracy. Enhanced features such as automatic systems and syringe heaters reduce errors and improve efficiency. Despite these advantages, there are still risks of extravasation, contrast-induced nephropathy and operator-related errors. Some mitigation strategies are rigorous training, routine maintenance, and patient screening. This review creates awareness toward recent advancements in HPCIs, their role in adverse event mitigation, and their potential to revolutionize imaging workflows to achieve safer and more effective patient care. EnglishHigh Pressure Contrast Injectors, Catheter Angiography (X-Ray), Computed Tomography (CT), Contrast-Induced Nephropathyhttp://ijcrr.com/abstract.php?article_id=4834http://ijcrr.com/article_html.php?did=4834

Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241171EnglishN2025January14Healthcare Comparison of Iron Chelators in the Management of Transfusion-Dependent Beta Thalassaemia Major Based on Serum Ferritin English0812Nilufar Akhtar Banu ChoudhuryEnglish Md. Abdul WohabEnglish Sazeda SultanaEnglish Md. Belayet HossainEnglish Introduction: Iron overload remains a critical challenge in transfusion-dependent beta thalassemia major patients, necessitating effective chelation strategies. This study evaluated the comparative efficacy of combination therapy (deferoxamine plus defera-sirox) versus deferasirox monotherapy in patients with severe iron overload. Methods: In this prospective, randomized controlled study, 50 transfusion-dependent beta thalassemia major patients with se- rum ferritin levels between 3,000-5,000 ng/mL were randomized into two groups. Group A (n=25) received combination therapy with subcutaneous deferoxamine (40-50 mg/kg/day, 5 days/week) plus oral deferasirox (20-30 mg/kg/day), while Group B (n=25) received deferasirox monotherapy (30-40 mg/kg/day). Patients were monitored over 12 months with regular assessment of serum ferritin levels, organ iron content, and safety parameters. Results: At 12 months, the combination therapy group demonstrated significantly greater reduction in serum ferritin levels compared to the monotherapy group (44.9% vs 24.9%, pEnglishBeta Thalassemia Major, Iron Chelation, Combination Therapy, Deferoxamine, Deferasirox, Serum Ferritin   Englishhttp://ijcrr.com/abstract.php?article_id=4835http://ijcrr.com/article_html.php?did=4835 1. Taher AT, Weatherall DJ, Cappellini MD. Thalassemia. Lancet. 2022;395(10233):1413-1426. 2. Cohen AR, Porter JB. Transfusion-related iron overload: Clini- cal implications and strategies for management. Blood Rev. 2021; 47:100785. 3. Musallam KM, Rivella S, Viprakasit V, Kattamis A. Iron overload in non-transfusion-dependent thalassemia: Clinical implications and therapeutic strategies. Haematologica. 2023;108(1):42-57. 4. Angelucci E, Pilo F. Management of iron overload before, dur- ing, and after hematopoietic stem cell transplantation for thalas- semia major. Hemoglobin. 2021;45(1):15-22. 5. Cappellini MD, Cohen A, Porter J. Guidelines for the manage- ment of transfusion dependent thalassemia (TDT), 4th edition. Thalassemia International Federation. 2021. 6. Porter JB, Shah FT. Iron overload in thalassemia and related con- ditions: Therapeutic goals and assessment of response to chela- tion therapies. Hematol Oncol Clin North Am. 2022;36(2):371- 389. 7. Farmaki K, Tzoumari I, Pappa C. Oral chelators in transfusion- dependent thalassemia major patients may prevent or reverse early cardiac dysfunction. Blood. 2021;116(18):3733-3740. 8. Yassin MA, Soliman AT, De Sanctis V. The impact of iron chela- tion adherence on morbidity and mortality in β-thalassemia ma- jor: A 10-year study. Acta Biomed. 2022; 93(1):e2022001. 9. Aydinok Y, Porter JB, Piga A. Prevalence and distribution of iron overload in patients with transfusion-dependent anemias differs across geographic regions: Results from the CORDELIA study. Eur J Haematol. 2023;110(1):31-40. 10. Pepe A, Meloni A, Pistoia L. MRI monitoring of iron overload in thalassemia major: multicentre validation of the T2* technique. Haematologica. 2022;107(8):1896-1906. 11. Cappellini MD, Porter JB, El-Beshlawy A, Li CK, Seymour JF, Elalfy M et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective multicenter EPIC study of deferasirox in 1744 patients with various transfusion-dependent anemias. Haematologica. 2023;95(4):557-566. 12. Porter JB, Evangeli M, El-Beshlawy A. Challenges of adher- ence and persistence with iron chelation therapy. Int J Hematol. 2021;94(5):453-460. 13. Sharma V, Piga A, Ghosh K. Long-term efficacy and safety of deferasirox in young children with transfusional haemosidero- sis: Results from a 5-year observational study. Br J Haematol. 2022;173(1):103-111. 14. Lal A, Porter J, Sweeters N. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Adv. 2023;7(1):23-30. 15. Thompson AA, Kwiatkowski JL, Kim HY. Patient-reported out- comes in transfusion-dependent β-thalassemia patients receiv- ing iron chelation therapy. Am J Hematol. 2023;98(2):167-175. 16. Chen H, Ataga KI, Caughey AB. Cost-effectiveness of iron chelation regimens in transfusion-dependent thalassemia major. Blood Adv. 2021;5(23):4851-4860. 17. Rodriguez MP, Grady RW, Hidalgo G. Iron chelation in thalas- semia: combined or monotherapy? The recent evidence. Ann N Y Acad Sci. 2022; 1368:140-147. 18. Kumar R, Piga A, Khalil A. Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron- overloaded patients with sickle cell disease. Br J Haematol. 2023;162(2):275-284. 19. Yang G, Liu R, Peng P. How iron overload patterns affect out- comes in patients with transfusion-dependent thalassemia: a cost-effectiveness